- Report
- October 2024
- 195 Pages
Global
From €3227EUR$3,545USD£2,741GBP
€3585EUR$3,939USD£3,045GBP
- Report
- April 2025
- 175 Pages
Global
From €4087EUR$4,490USD£3,471GBP
- Report
- March 2025
- 200 Pages
Global
From €4087EUR$4,490USD£3,471GBP
- Report
- February 2025
- 200 Pages
Global
From €4087EUR$4,490USD£3,471GBP
- Report
- November 2023
- 30 Pages
Global
From €2503EUR$2,750USD£2,126GBP
- Report
- April 2025
- 50 Pages
Global
From €2412EUR$2,650USD£2,049GBP
- Report
- April 2025
- 50 Pages
Global
From €2412EUR$2,650USD£2,049GBP
Dacarbazine is a chemotherapy drug used to treat certain types of lymphoma, a type of cancer that affects the lymphatic system. It is a nitrogen mustard alkylating agent, meaning it works by damaging the DNA of cancer cells, preventing them from growing and dividing. Dacarbazine is typically used in combination with other drugs, such as bleomycin, vinblastine, and doxorubicin, to increase its effectiveness. It is usually administered intravenously, but can also be taken orally.
Dacarbazine is a widely used drug for the treatment of lymphoma, and is available in both generic and branded forms. It is typically prescribed as a first-line treatment for Hodgkin's lymphoma, and is also used to treat other types of lymphoma, such as non-Hodgkin's lymphoma and cutaneous T-cell lymphoma.
Several companies manufacture and market dacarbazine, including Bristol-Myers Squibb, Teva Pharmaceuticals, and Mylan. Other companies, such as Hospira and Baxter, produce generic versions of the drug. Show Less Read more